MBRX
Moleculin Biotech, Inc.NASDAQHealthcare$2.32+0.00%ClosedMarket Cap: $2.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.83
P/S
0.00
EV/EBITDA
0.23
DCF Value
$0.45
FCF Yield
-810.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
502.7%
ROA
-108.1%
ROIC
-162.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-7.5M | $15.6M | $4.83 | — |
| FY 2025 | $0.00 | -Infinity% | $-25.1M | $-33.6M | $-28.42 | — |
| Q3 2025 | $0.00 | -Infinity% | $-5.9M | $-25.4M | $-17.00 | — |
| Q2 2025 | $0.00 | -Infinity% | $-5.7M | $-7.6M | $-12.25 | — |
| Q1 2025 | $0.00 | NaN% | $-5.9M | $-6.4M | $-1,722.00 | — |
| Q4 2024 | $0.00 | -Infinity% | $-6.6M | $-1.9M | $-14.00 | — |
| FY 2024 | $0.00 | NaN% | $-26.6M | $-21.8M | $-158.00 | — |
| Q3 2024 | $0.00 | NaN% | $-7.1M | $-10.6M | $-71.25 | — |
| Q2 2024 | $0.00 | NaN% | $-6.2M | $-4.3M | $-42.50 | — |
| Q1 2024 | $0.00 | NaN% | $-6.7M | $-5.0M | $-50.50 | — |
| Q4 2023 | $0.00 | -Infinity% | $-8.9M | $-10.3M | $-128.25 | — |
| FY 2023 | $0.00 | NaN% | $-29.6M | $-29.8M | $-376.75 | — |